ABBOTT LABORATORIES (ABT) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-03-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-03-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-03-31..
Borrowing debt
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 4.41B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 29.64B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 110.43B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | (m) | $4.41B | $29.64B | (m) | (m) | $110.43B | (m) |
| 2025-12-31 | (m) | (m) | $3.03B | $9.90B | (m) | (m) | $86.71B | (m) |
| 2025-09-30 | (m) | (m) | $1.34B | $11.60B | (m) | (m) | $84.18B | (m) |
| 2025-06-30 | (m) | (m) | $507.00M | $12.93B | (m) | (m) | $84.00B | (m) |
| 2025-03-31 | (m) | (m) | $506.00M | $12.74B | (m) | (m) | $81.45B | (m) |
| 2024-12-31 | (m) | (m) | $1.50B | $12.63B | (m) | (m) | $81.41B | (m) |
| 2024-09-30 | (m) | (m) | $2.15B | $12.82B | (m) | (m) | $74.36B | (m) |
| 2024-06-30 | (m) | (m) | $1.61B | $13.14B | (m) | (m) | $73.02B | (m) |
| 2024-03-31 | (m) | (m) | $2.01B | $12.58B | (m) | (m) | $72.47B | (m) |
| 2023-12-31 | (m) | (m) | $1.08B | $13.60B | (m) | (m) | $73.21B | (m) |
| 2023-09-30 | (m) | (m) | $1.05B | $14.48B | (m) | (m) | $72.09B | (m) |
| 2023-06-30 | (m) | (m) | $2.28B | $14.56B | (m) | (m) | $73.35B | (m) |
| 2023-03-31 | (m) | (m) | $2.29B | $14.62B | (m) | (m) | $73.79B | (m) |
| 2022-12-31 | (m) | (m) | $2.25B | $14.52B | (m) | (m) | $74.44B | (m) |
| 2022-09-30 | (m) | (m) | $1.12B | $15.30B | (m) | (m) | $72.80B | (m) |
| 2022-06-30 | (m) | (m) | $5.00M | $16.75B | (m) | (m) | $74.20B | (m) |
| 2022-03-31 | (m) | (m) | $4.00M | $17.09B | (m) | (m) | $74.01B | (m) |
| 2021-12-31 | (m) | (m) | $754.00M | $17.30B | (m) | (m) | $75.20B | (m) |
| 2021-09-30 | (m) | (m) | $754.00M | $17.45B | (m) | (m) | $73.80B | (m) |
| 2021-06-30 | (m) | (m) | $755.00M | $17.55B | (m) | (m) | $73.27B | (m) |
| 2021-03-31 | (m) | (m) | $756.00M | $17.49B | (m) | (m) | $72.78B | (m) |
| 2020-12-31 | (m) | (m) | $7.00M | $18.53B | (m) | (m) | $72.55B | (m) |
| 2020-09-30 | (m) | (m) | $6.00M | $18.35B | (m) | (m) | $69.04B | (m) |
| 2020-06-30 | (m) | (m) | $1.29B | $18.18B | (m) | (m) | $68.78B | (m) |
| 2020-03-31 | (m) | (m) | $1.26B | $16.80B | (m) | (m) | $66.78B | (m) |
| 2019-12-31 | (m) | (m) | $1.28B | $16.66B | (m) | (m) | $67.89B | (m) |
| 2019-09-30 | (m) | (m) | $1.25B | $17.64B | (m) | (m) | $68.54B | (m) |
| 2019-06-30 | (m) | (m) | $8.00M | $18.98B | (m) | (m) | $68.43B | (m) |
| 2019-03-31 | (m) | (m) | $8.00M | $18.84B | (m) | (m) | $67.61B | (m) |
| 2018-12-31 | (m) | (m) | $7.00M | $19.36B | (m) | (m) | $67.17B | (m) |
| 2018-09-30 | (m) | (m) | $4.06B | $19.28B | (m) | (m) | $71.64B | (m) |
| 2018-06-30 | (m) | (m) | $506.00M | $19.82B | (m) | (m) | $68.42B | (m) |
| 2018-03-31 | (m) | (m) | $507.00M | $21.15B | (m) | (m) | $70.91B | (m) |
| 2017-12-31 | (m) | (m) | $508.00M | $27.21B | (m) | (m) | $76.25B | (m) |
| 2017-09-30 | (m) | (m) | $504.00M | $23.31B | (m) | (m) | $72.25B | (m) |
| 2017-06-30 | (m) | (m) | $3.00M | $23.81B | (m) | (m) | $71.15B | (m) |
| 2017-03-31 | (m) | (m) | $3.00M | $23.76B | (m) | (m) | $70.89B | (m) |
| 2016-12-31 | (m) | (m) | $3.00M | $20.68B | (m) | (m) | $52.67B | (m) |
| 2016-09-30 | (m) | (m) | $4.00M | $5.97B | (m) | (m) | $39.50B | (m) |
| 2016-06-30 | (m) | (m) | $4.00M | $6.02B | (m) | (m) | $39.83B | (m) |
| 2016-03-31 | (m) | (m) | $3.00M | $5.98B | (m) | (m) | $39.64B | (m) |
| 2015-12-31 | (m) | (m) | $3.00M | $5.87B | (m) | (m) | $41.25B | (m) |
| 2015-09-30 | (m) | (m) | $32.00M | $5.95B | (m) | (m) | $41.73B | (m) |
| 2015-06-30 | (m) | (m) | $32.00M | $5.86B | (m) | (m) | $44.13B | (m) |
| 2015-03-31 | (m) | (m) | $51.00M | $5.93B | (m) | (m) | $43.09B | (m) |
| 2014-12-31 | (m) | (m) | $55.00M | $3.41B | (m) | (m) | $41.27B | (m) |
| 2014-09-30 | (m) | (m) | $206.00M | $3.72B | (m) | (m) | $42.51B | (m) |
| 2014-06-30 | (m) | (m) | $9.00M | $3.40B | (m) | (m) | $41.48B | (m) |
| 2014-03-31 | (m) | (m) | $8.00M | $3.39B | (m) | (m) | $41.66B | (m) |
| 2013-12-31 | (m) | (m) | $9.00M | $3.39B | (m) | (m) | $42.95B | (m) |
| 2013-09-30 | (m) | (m) | $264.01M | $3.40B | (m) | (m) | $44.13B | (m) |
| 2013-06-30 | (m) | (m) | $264.16M | $3.41B | (m) | (m) | $42.90B | (m) |
| 2013-03-31 | (m) | (m) | $277.60M | $3.47B | (m) | (m) | $42.69B | (m) |
| 2012-12-31 | (m) | (m) | $308.82M | $18.09B | (m) | (m) | $67.23B | (m) |
| 2012-09-30 | (m) | (m) | $1.02B | $12.05B | (m) | (m) | $63.26B | (m) |
| 2012-06-30 | (m) | (m) | $1.02B | $12.00B | (m) | (m) | $61.86B | (m) |
| 2012-03-31 | (m) | (m) | $1.03B | $11.86B | (m) | (m) | $62.42B | (m) |
| 2011-12-31 | (m) | (m) | $1.03B | $12.04B | (m) | (m) | $60.28B | (m) |
| 2011-09-30 | (m) | (m) | $35.00M | $13.10B | (m) | (m) | $59.63B | (m) |
| 2011-06-30 | (m) | (m) | $25.84M | $12.63B | (m) | (m) | $62.00B | (m) |
| 2011-03-31 | (m) | (m) | $1.53B | $12.53B | (m) | (m) | $61.65B | (m) |
| 2010-12-31 | (m) | (m) | $2.04B | $12.52B | (m) | (m) | $59.46B | (m) |
| 2010-09-30 | (m) | (m) | $2.22B | $12.91B | (m) | (m) | $57.37B | (m) |
| 2010-06-30 | (m) | (m) | $2.22B | $12.61B | (m) | (m) | $53.38B | (m) |
| 2010-03-31 | (m) | (m) | $718.09M | $10.88B | (m) | (m) | $53.36B | (m) |
| 2009-12-31 | (m) | (m) | $211.18M | $11.27B | (m) | (m) | $52.42B | (m) |
| 2009-09-30 | (m) | (m) | $35.11M | $11.58B | (m) | (m) | $49.85B | (m) |
| 2009-06-30 | (m) | (m) | $36.10M | $11.37B | (m) | (m) | $47.63B | (m) |
| 2008-12-31 | (m) | (m) | $1.04B | $8.71B | (m) | (m) | $42.42B | (m) |
| 2007-12-31 | (m) | (m) | $898.55M | $9.49B | (m) | (m) | $39.71B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |